Clinical Trial Update: RT Plus EGFR-TKI for Wild-type NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update examines using radiation therapy plus an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for wild-type non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Hangzhou Cancer Hospital | Conditions: Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) | Phase 2 | Status: UNKNOWN